Mishra Dinesh Kumar, Balekar Neelam, Mishra Pradyumna Kumar
IPS Academy, College of Pharmacy, A. B. Road, Indore, MP, 452 012, India.
Department of Molecular Biology, National Institute for Research in Environmental Health, Indian Council of Medical Research (ICMR), Bhopal, India.
Drug Deliv Transl Res. 2017 Apr;7(2):346-358. doi: 10.1007/s13346-016-0352-5.
The promise of RNA interference (RNAi) technology in cancer therapeutics aims to deliver small interfering RNA (siRNA) for silencing of gene expression in cell type-specific pathway. However, the challenge for the delivery of stable siRNA is hindered by an immune-hostile tumor microenvironment and physiological barriers of the circulatory system. Therefore, the development and validation of safe, stable, and efficient nanoengineered delivery systems are highly essential for effective delivery of siRNA into cancer cells. This review focuses on gene-silencing mechanisms, challenges to siRNA delivery, design and delivery of nanocarrier systems, ongoing clinical trials, and translational prospects for siRNA-mediated cancer therapeutics.
RNA干扰（RNAi）技术在癌症治疗中的前景旨在递送小干扰RNA（siRNA），以沉默细胞类型特异性途径中的基因表达。然而，稳定siRNA递送面临的挑战受到免疫敌对的肿瘤微环境和循环系统生理屏障的阻碍。因此，开发和验证安全、稳定且高效的纳米工程递送系统对于将siRNA有效递送至癌细胞至关重要。本综述聚焦于基因沉默机制、siRNA递送面临的挑战、纳米载体系统的设计与递送、正在进行的临床试验以及siRNA介导的癌症治疗的转化前景。
